Compare Innodata Inc (INOD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Novo Nordisk A/S — how do they compare? Innodata Inc trades at $61.2 (market cap $2.10B), while Novo Nordisk A/S trades at $38.52 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 78.7× Innodata Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Novo Nordisk A/S for 116 Days on average.
| INOD | NVO | |
|---|---|---|
Market Cap | $2.10B | $165.31B |
Volume | 989,493 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $121.50 | $63.98 |
52-Week Low | $34.45 | $35.29 |
Typical Hold Time | 19 Days | 116 Days |
Enterprise Value | $1.86B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innodata (INOD) trades at $60.80, down 4.12% today amid bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and robust profitability (37.74% ROE, 14.66% net margin). Recent quarterly results exceeded expectations, with Q1 2026 EPS of $0.42 beating estimates by 223%. The company is expanding into motion-capture AI and agentic reinforcement learning, positioning for growth in the AI infrastructure sector.
Despite premium valuations (P/E 47.43), INOD's strong execution and AI market positioning offer upside potential. Key risks include customer concentration and competitive pressures. Analyst consensus is bullish (66.7% buy ratings), though technical indicators suggest near-term caution with the stock trading below key resistance levels.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
